Amryt Pharma's LON:AMYT) Rory Nealon presents at the Proactive One2One virtual conference.
Amryt Pharma is a commercial stage pharmaceutical company focused on developing and delivering innovative new treatments to help improve the lives of people with rare and orphan diseases.
The company recently outligned plans to share additional encouraging data on its recent successful phase III study of FILSUVEZ to the medical and financial communities.
Price: 192 GBX
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...
In exchange for publishing services rendered by the Company on behalf of Amryt Pharma PLC named herein, including the promotion by the Company of Amryt Pharma PLC in any Content on the Site, the Company receives from...
FOR OUR FULL DISCLAIMER CLICK HERE
Amryt Pharma PLC (NASDAQ:AMYT) (LON:AMYT) CEO Joe Wiley tells Proactive the group has raised $40M from leading biotech investors in a private placement, with a tranche of the proceeds being used to in-license or invest in rare disease technologies. Wiley says investors include Stonepine...
Prev article
